Corporate

Hikma Appoints Sagar Patel as European Commercial Head for Injectables

London, 4 October 2018 -- As part of its global growth strategy, Hikma Pharmaceuticals PLC (‘Hikma’) (LSE: HIK), has appointed Sagar Patel to a newly created London-based role as the European Commercial Head for its Injectables business, effective immediately.

Reporting to the CEO of Hikma’s Injectables Division, Riad Mechlaoui, Mr. Patel will focus on developing business growth strategies and partnerships with key stakeholders across the region. He joins the company from Fresenius Kabi, where he most recently held the role of Senior VP Global Alliance Management and Third-Party Manufacturing.

 

Commenting on Mr. Patel’s appointment, Mr. Mechlaoui said, “Sagar’s leadership skills, strategic business planning and excellent commercial experience will be a major asset for our Injectables Division and our European business as we look to grow internationally.”

 

Mr. Patel joins Hikma at a time of organizational change to boost the Group’s senior leadership capabilities and expand its reach across Europe. Having worked for many years in pharmaceutical and FMCG businesses, he brings a breadth of commercial experience that adds significant bandwidth to Hikma’s ability to maximize its portfolio.

 

Mr. Patel holds a Chemical Engineering with Industrial Studies degree from the University of Bradford and has completed multiple senior executive development programmes through world-class business schools. Commenting on his appointment, he said, “I am extremely pleased to be joining Hikma in this key leadership role and look forward to making a significant impact by accelerating the growth of the Injectables Division right across the continent.”